123828-68-2

Basic information

• Product Name: 2H-Pyran-5-carboxylicacid, 3-ethenyl-2-(b-D-glucopyranosyloxy)-3,4-dihydro-4-[[(1S)-2,3,4,9-tetrahydro-2-methyl-1H-pyrido[3,4-b]indol-1-yl]methyl]-,(2S,3R,4S)-
• Synonyms: 2H-Pyran-5-carboxylicacid, 3-ethenyl-2-(b-D-glucopyranosyloxy)-3,4-dihydro-4-[(2,3,4,9-tetrahydro-2-methyl-1H-pyrido[3,4-b]indol-1-yl)methyl]-,[2S-[2a,3b,4b(R*)]]-; 1H-Pyrido[3,4-b]indole, 2H-pyran-5-carboxylic acid deriv.;(-)-Palicoside; Palicoside
• CAS NO: 123828-68-2
• Molecular Formula: C27H34 N2 O9
• Molecular Weight: 530.575
• Mol File: 123828-68-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2H-Pyran-5-carboxylicacid, 3-ethenyl-2-(b-D-glucopyranosyloxy)-3,4-dihydro-4-[[(1S)-2,3,4,9-tetrahydro-2-methyl-1H-pyrido[3,4-b]indol-1-yl]methyl]-,(2S,3R,4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-5-carboxylicacid, 3-ethenyl-2-(b-D-glucopyranosyloxy)-3,4-dihydro-4-[[(1S)-2,3,4,9-tetrahydro-2-methyl-1H-pyrido[3,4-b]indol-1-yl]methyl]-,(2S,3R,4S)-(123828-68-2)
• EPA Substance Registry System: 2H-Pyran-5-carboxylicacid, 3-ethenyl-2-(b-D-glucopyranosyloxy)-3,4-dihydro-4-[[(1S)-2,3,4,9-tetrahydro-2-methyl-1H-pyrido[3,4-b]indol-1-yl]methyl]-,(2S,3R,4S)-(123828-68-2)

Safety Data

• Hazardous Substances Data: 123828-68-2(Hazardous Substances Data)

Upstream product

• 19351-63-4 secologanin 
• 61-49-4 [2-(1H-indol-3-yl)-ethyl]-methylamine 
• 68727-52-6 dolichantoside 

Downstream Products

• 56519-07-4 akagerine 

Relevant articles and documents

Final solution on the long-standing structural arguments on the c-3 stereochemistries of three glucoindole alkaloids: Palicoside, dolichantoside, and isodolichantoside - Through chemical conversions and spectroscopic studies

Three natural strictosidine/vincoside-class glucoindole alkaloids have been chemically correlated with strictosidinic acid possessing a rigorously established stereostructure. The C-3 stereochemistry of palicoside, dolichantoside, and isodolichantoside has been firmly proved to be (S), (S), and (R), respectively.